内异停方对子宫内膜异位症血清VEGF及在位内膜VEGFR-2的影响
|
摘要
目的:评价内异停方治疗子宫内膜异位症(EMs)疗效,观察内异停对EMs患者血清VEGF水平及在位内膜VEGFR-2的影响。方法:将76例EMs的患者分为两组,治疗组采用内异停方治疗,对照组采用桂枝茯苓胶囊治疗,2个月为1个疗程,观察2个疗程,评价临床疗效,并以ELISA方法检测血清VEGF,以免疫组化的方法检测在位内膜VEGFR-2的变化。结果:内异停方治疗EMs总有效率达88. 00%,优于对照组桂枝茯苓胶囊(58. 33%)(P <0. 05);内异停可明显降低血清CA125及VEGF水平(P <0. 05),与对照组相当;内异停组与对照组(未用药)在位内膜VEGFR-2比较,VEGFR-2表达明显下降。结论:内异停方治疗EMs有效,疗效优于桂枝茯苓胶囊,值得临床运用推广。内异停方可能通过降低EMs血清VEGF水平及在位内膜VEGFR-2水平发挥治疗作用。
Objective:It is to evaluate the curative effect of Neiyiting Prescription on endometriosis( EMs) and observe the influences of Neiyiting Prescription on the levels of VEGF in serum and VEGFR-2 in eutopic endometrium of endometriosis patients. Methods:A total of 76 EMs patients were divided into two groups,adopting Neiyiting Prescription for the therapy group and Cinnamom Twig Poria Capsule for the control group. Two months was as one course of treatment,observing for 2 courses. We evaluated the clinical curative effect,tested the change of VEGF in serum with ELISA method and the change of VEGFR-2 in eutopic endometrium with immunohistochemical method. Results:The total effective rate of Neiyiting Prescription for treatment of EMs was up to 88. 00%,better than that of the control group(58. 33%)( P < 0. 05). Neiyiting Prescription could obviously lower the levels of CA125 and VEGF in serum( P < 0. 05),equivalent to those of the control group. Compared with the control group( not given medicine) in terms of the VEGFR-2 in eutopic endometrium,Neiyiting Prescription group could obviously lower the expression of VEGFR-2. Conclusion:Neiyiting Prescription is effective in treatment of EMs,and has better curative effects than Cinnamom Twig Poria Capsule,and is worthy of clinical application and promotion. Neiyiting Prescription could possibly play a curative role by lowering the level of VEGF in serum and the level of VEGFR-2 in eutopic endometrium of EMs patients.
Objective:It is to evaluate the curative effect of Neiyiting Prescription on endometriosis( EMs) and observe the influences of Neiyiting Prescription on the levels of VEGF in serum and VEGFR-2 in eutopic endometrium of endometriosis patients. Methods:A total of 76 EMs patients were divided into two groups,adopting Neiyiting Prescription for the therapy group and Cinnamom Twig Poria Capsule for the control group. Two months was as one course of treatment,observing for 2 courses. We evaluated the clinical curative effect,tested the change of VEGF in serum with ELISA method and the change of VEGFR-2 in eutopic endometrium with immunohistochemical method. Results:The total effective rate of Neiyiting Prescription for treatment of EMs was up to 88. 00%,better than that of the control group(58. 33%)( P < 0. 05). Neiyiting Prescription could obviously lower the levels of CA125 and VEGF in serum( P < 0. 05),equivalent to those of the control group. Compared with the control group( not given medicine) in terms of the VEGFR-2 in eutopic endometrium,Neiyiting Prescription group could obviously lower the expression of VEGFR-2. Conclusion:Neiyiting Prescription is effective in treatment of EMs,and has better curative effects than Cinnamom Twig Poria Capsule,and is worthy of clinical application and promotion. Neiyiting Prescription could possibly play a curative role by lowering the level of VEGF in serum and the level of VEGFR-2 in eutopic endometrium of EMs patients.
引文
[1] Novella-Maestre E,Carda C,Ruiz-Sauri A. Identification and quantification of dopamine receptor 2 in human eutopicand ectopic endometrium:A novel molecular target for endometriosis therapy[J]. Biol Reprod,2010,83(5):866-873.
[2] Harper SJ,Bates DO. VEGF-A splicing:the key to anti-angiogenic therapeutics?[J]. Nat Rev Cancer,2008,8(11):880-887.
[3]时燕萍,傅友丰,王斌,等.内异停对离体培养的子宫内膜异位症的异位子宫内膜细胞的直接抑制作用[J].中华中医药学刊,2005,23(5):896-898.
[4]董倩,李佩玲,孙美玲,等. VEGF及其受KDR在子宫内膜异位症中的表达及意义[J].现代妇产科进展,2012,21(11):873-877.
[5] Guo Y,Chen Y,Liu LB,et al. IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8[J]. Int J Clin ExpPathol,2013,6:2011-2020.
[6]尉伟东,阮菲,涂飞霞,等.细胞因子信号传送阻抑物-3和caspase-3在子宫内膜异位症中的表达及其相关性[J].中华病理学杂志,2013,42:515-518.
[7] Chang KK,Liu LB,Jin LP,et al. NME1 suppression of endometrial stromal cells promotes angiogenesis in the endometriotic milieu via stimulating the secretion of IL-8 and VEGF[J]. Int J Clin Exp Pathol,2013,6:2030-2038.
[8] Huang F,Cao J,Liu Q,et al. MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1βinduced in human endometriosis stromal cells in vitro[J]. Int J Clin Exp Pathol,2013,6:2129-2136.
[9] MACHADO D E,BERARDO P T,LANDGRAF R G,et al. Aselective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model[J]. Fertility and Sterility,2010,93(8):2674-2679.
[10]王菲菲,龚晔晟,张洁琼.子宫内膜异位症患者血清和腹腔液中VEGF、IL-6、IL-8的表达情况及临床意义[J].北京医学2015,37(2):138-141.
[11]王军玲,罗淑红.血管内皮生长因子及其可溶性受体在子宫内膜异位症患者血清、腹腔液中的表达及意义[J].中国计划生育和妇产科,2016,8(4):47-58.
[12]刘洋,散琴,熊莹莹,等.子宫内膜异位症患者血清CA125、EMAb、ERA-78、EPO、VEGF水平的临床意义[J].中国计划生育学杂志,2017,25(7):479-481.
[13]董倩,李佩玲,孙美玲,等. VEGF及其受KDR在子宫内膜异位症中的表达及意义[J].现代妇产科进展,2012,21(11):873-877.
[14]范蕊,马楠.子宫内膜异位症患者血清中VEGF和IGF-Ⅰ的表达及其相关性[J].中国妇幼保健,2012,27(21):3328-3330.
[15]丛楠.血管内皮生长因子在异位和在位子宫内膜中的变化及其意义[J].中国社区医师,2017,33(21):102-104.
[16]崔明华,李龙珠,刘家军.桂枝茯苓丸对子宫内膜异位症模型大鼠血管内皮生长因子表达的影响[J].实用药物与临床,2015,18(9):1023-1026.
[17]韩晶,文英.桂枝茯苓丸对子宫内膜异位症患者血清MAPK、ERK和VEGF水平影响研究[J].中国生化药物杂志,2015,35(12):125-127.
[18]陶蓉,于翠革.桂枝茯苓丸对子宫内膜异位症患者MEK-2、pERK和VEGF表达影响[J].辽宁中医药大学学报,2016,18(12):131-134.
[2] Harper SJ,Bates DO. VEGF-A splicing:the key to anti-angiogenic therapeutics?[J]. Nat Rev Cancer,2008,8(11):880-887.
[3]时燕萍,傅友丰,王斌,等.内异停对离体培养的子宫内膜异位症的异位子宫内膜细胞的直接抑制作用[J].中华中医药学刊,2005,23(5):896-898.
[4]董倩,李佩玲,孙美玲,等. VEGF及其受KDR在子宫内膜异位症中的表达及意义[J].现代妇产科进展,2012,21(11):873-877.
[5] Guo Y,Chen Y,Liu LB,et al. IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8[J]. Int J Clin ExpPathol,2013,6:2011-2020.
[6]尉伟东,阮菲,涂飞霞,等.细胞因子信号传送阻抑物-3和caspase-3在子宫内膜异位症中的表达及其相关性[J].中华病理学杂志,2013,42:515-518.
[7] Chang KK,Liu LB,Jin LP,et al. NME1 suppression of endometrial stromal cells promotes angiogenesis in the endometriotic milieu via stimulating the secretion of IL-8 and VEGF[J]. Int J Clin Exp Pathol,2013,6:2030-2038.
[8] Huang F,Cao J,Liu Q,et al. MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1βinduced in human endometriosis stromal cells in vitro[J]. Int J Clin Exp Pathol,2013,6:2129-2136.
[9] MACHADO D E,BERARDO P T,LANDGRAF R G,et al. Aselective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model[J]. Fertility and Sterility,2010,93(8):2674-2679.
[10]王菲菲,龚晔晟,张洁琼.子宫内膜异位症患者血清和腹腔液中VEGF、IL-6、IL-8的表达情况及临床意义[J].北京医学2015,37(2):138-141.
[11]王军玲,罗淑红.血管内皮生长因子及其可溶性受体在子宫内膜异位症患者血清、腹腔液中的表达及意义[J].中国计划生育和妇产科,2016,8(4):47-58.
[12]刘洋,散琴,熊莹莹,等.子宫内膜异位症患者血清CA125、EMAb、ERA-78、EPO、VEGF水平的临床意义[J].中国计划生育学杂志,2017,25(7):479-481.
[13]董倩,李佩玲,孙美玲,等. VEGF及其受KDR在子宫内膜异位症中的表达及意义[J].现代妇产科进展,2012,21(11):873-877.
[14]范蕊,马楠.子宫内膜异位症患者血清中VEGF和IGF-Ⅰ的表达及其相关性[J].中国妇幼保健,2012,27(21):3328-3330.
[15]丛楠.血管内皮生长因子在异位和在位子宫内膜中的变化及其意义[J].中国社区医师,2017,33(21):102-104.
[16]崔明华,李龙珠,刘家军.桂枝茯苓丸对子宫内膜异位症模型大鼠血管内皮生长因子表达的影响[J].实用药物与临床,2015,18(9):1023-1026.
[17]韩晶,文英.桂枝茯苓丸对子宫内膜异位症患者血清MAPK、ERK和VEGF水平影响研究[J].中国生化药物杂志,2015,35(12):125-127.
[18]陶蓉,于翠革.桂枝茯苓丸对子宫内膜异位症患者MEK-2、pERK和VEGF表达影响[J].辽宁中医药大学学报,2016,18(12):131-134.